lncRNA RP11-838N2.3 Promoted Cisplatin Resistance in Lung Adenocarcinoma

Table 2

Clinical characteristics between the cisplatin-sensitive group and cisplatin-insensitive group.

Term	Sensitive group ()	Insensitive group ()
Sex			0.148	0.701
Male	12	17
Female	13	15
TMN stage			0.686	0.953
Ia	2	1
Ib	6	8
IIa	7	9
IIb	5	7
IIIa	5	7
Histological degree			0.338	0.987
Poor	4	5
Poor-moderate	5	7
Moderate	7	10
Moderate-high	3	5
High	5	5
Lymph node metastasis			0.004	0.952
Yes	8	10
No	17	22
Smoking			0.002	0.962
Yes	10	13
No	15	19